Mirdametinib (PD0325901) is an orally active, selective, non-ATP-competitive MEK inhibitor (IC50: 0.33 nM). It blocks MEK1/2 activation, suppresses p-ERK1/2 expression, and induces apoptosis, demonstrating broad-spectrum anticancer activity in human tumor xenografts. Reagent-grade; for laboratory research purposes only.
Usually ships within 24 hours.